D. Magdolna

Factors affecting prognosis in patients treated with bevacizumab plus paclitaxel as first-line chemotherapy for HER2-negative metastatic breast cancer: an international pooled analysis of individual patient data from four prospective observational studies

A. Schneeweiss, O. Gluz, H. Yamashiro, 2022, Breast Cancer.

Factors affecting prognosis in patients treated with bevacizumab plus paclitaxel as first-line chemotherapy for HER2-negative metastatic breast cancer: an international pooled analysis of individual patient data from four prospective observational studies

A. Schneeweiss, O. Gluz, H. Yamashiro, 2022, Breast Cancer.